As a treatment for alcohol intoxication and liver disease,<unk>  is typically given intravenously as immediate release formulation. Acute alcohol intoxication In clinical studies,<unk>  has been reported to reduce half-life of ethanol in healthy volunteers and in acutely intoxicated patients; to accelerate the metabolism of alcohol and acetaldehyde into less toxic higher ketones and to improve their urinary clearance; to restore laboratory variables such as alcohol, ammonia, γ-GT, and alanine aminotransferase; and to improve clinical symptoms of alcohol intoxication, including psychomotor agitation, depression, aggressiveness, and equilibrium disorders. There is also evidence that<unk>  has an effect on reducing craving for alcohol. Data from clinical studies also support an effect of<unk>  on reducing indices of liver cell necrosis and fat accumulation in alcoholic fatty liver. Liver disease<unk>  may block the differentiation step of preadipocytes by inhibiting CREB phosphorylation and binding to the cAMP response element, thereby repressing CCAAT/enhancer-binding protein b during hormone-induced adipogenesis.<unk> , when given in an immediate release form in doses from 300 mg twice a day to 500 mg three times a day of up to 3 months, has been shown to improve biochemical indices of liver function as well as reduce ultrasonic evidence of fatty liver disease.
Metadoxine
Etifoxine
Levomefolic acid
Pyridoxine
Boroline
Retinol
Quinine
Phenothrin